State Street Corp Athira Pharma, Inc. Transaction History

State Street Corp

$2.41 Trillion
Q3 2024

A detailed history of State Street Corp transactions in Athira Pharma, Inc. stock. As of the latest transaction made, State Street Corp holds 107,781 shares of ATHA stock, worth $70,057. This represents 0.0% of its overall portfolio holdings.

Number of Shares

107,781

Previous 107,781 -0.0%

Holding current value

$70,057

Previous $285,000 83.16%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$1.9 - $3.16 $20,330 - $33,812	-10,700 Reduced 9.03%	107,781 $217,000
Q2 2023 Aug 14, 2023	SELL	$2.36 - $3.59 $1.57 Million - $2.38 Million	-664,129 Reduced 84.86%	118,481 $349,000
Q1 2023 May 15, 2023	BUY	$2.26 - $4.22 $8,129 - $15,179	3,597 Added 0.46%	782,610 $1.96 Million
Q4 2022 Feb 14, 2023	SELL	$2.76 - $3.71 $8,669 - $11,653	-3,141 Reduced 0.4%	779,013 $2.47 Million
Q3 2022 Nov 15, 2022	SELL	$2.93 - $3.96 $375,687 - $507,755	-128,221 Reduced 14.08%	782,154 $2.32 Million
Q2 2022 Aug 15, 2022	BUY	$2.74 - $13.43 $226,874 - $1.11 Million	82,801 Added 10.01%	910,375 $2.78 Million
Q1 2022 May 16, 2022	BUY	$8.96 - $13.51 $2.08 Million - $3.14 Million	232,280 Added 39.02%	827,574 $11.2 Million
Q4 2021 Feb 14, 2022	BUY	$9.17 - $16.39 $1.01 Million - $1.8 Million	110,041 Added 22.68%	595,294 $7.76 Million
Q3 2021 Nov 15, 2021	BUY	$9.15 - $11.09 $475,205 - $575,959	51,935 Added 11.99%	485,253 $4.55 Million
Q2 2021 Aug 16, 2021	BUY	$10.24 - $20.87 $2.26 Million - $4.61 Million	220,967 Added 104.06%	433,318 $4.44 Million
Q1 2021 May 17, 2021	BUY	$16.9 - $29.77 $261,882 - $461,315	15,496 Added 7.87%	212,351 $3.91 Million
Q4 2020 Feb 16, 2021	BUY	$16.48 - $34.3 $3.24 Million - $6.75 Million	196,855 New	196,855 $6.74 Million

Others Institutions Holding ATHA

# of Institutions

Shares Held

16.9M

Call Options Held

112K

Put Options Held

68K

View Full List

About Athira Pharma, Inc.

Ticker ATHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,817,700
Market Cap $24.6M
Description
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...

More about ATHA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account

State Street Corp Athira Pharma, Inc. Transaction History